Document is current
Any future updates will be listed below
-
Authors
Meganathan, Kesavan
Prakasam, Ramachandran
Baldridge, Dustin
Gontarz, Paul
Zhang, Bo
Urano, Fumihiko
Bonni, Azad
Maloney, Susan E.
Turner, Tychele N.
Huettner, James E.
Constantino, John N.
Kroll, Kristen L. https://orcid.org/0000-0002-5450-6694
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (U01 HG007530, R01NS114551)
National Institute of Mental Health (R01MH124808)
M-CM Network (n/a)
Jakob Gene Fund (n/a)
Children's Discovery Institute (CDI-LI-2019-819)
National Institute of Child Health and Human Development (U54 HD087011-05S1)
National Institute of Diabetes and Digestive and Kidney Diseases (DK112921, DK020579)
- License Information
-
More Information
Article History
Received: 23 April 2021
Accepted: 30 June 2021
First Online: 28 July 2021
Declarations
:
: Subjects were consented for iPSC line generation by the Washington University Institutional Review Board of the Human Research Protection Office under human studies protocol #201409091 (Dr. John Constantino).
: Consent to publish data was provided by all subjects.
: F. Urano received JTV-519 from the National Center for Advancing Translational Sciences for developing small molecule-based therapies for ER stress-related disorders and shares the intellectual property rights related to JTV-519 with the National Institutes of Health. F. Urano is an inventor of the patent related to ER calcium stabilizers, 10,441,574, B2 TREATMENT FOR WOLFRAM SYNDROME AND OTHER ER STRESS DISORDERS. The other authors declare that they have no competing interests.
